Sarcopenic Obesity and Its Impact on Quality of Life: A Concise Review

Khanna, Archana; Kumari, Mangalam

doi:10.2174/1874609816666230525161020

Cited by 4 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the concomitant presence of obesity, sarcopenia, and osteoporosis represents a dreadful trio potentially occurring in postmenopausal women and individuals of advanced age, as each of these conditions is related with adverse outcomes in terms of morbidity, quality of life, and mortality [16], recent works have tried to identify clinical potential early biomarkers and factors further involved in OSO development [17]. Interestingly, a few studies have suggested that high serum ferritin levels are strongly linked to metabolic syndrome, obesity, impaired muscle quality, and sarcopenia [18].…”

Section: Biomarkersmentioning

confidence: 99%

Sarcopenic obesity and the impact on bone health

Migliaccio,

Mocini,

Minnetti

et al. 2024

Current Opinion in Clinical Nutrition &Amp; Metabolic Care

View full text Add to dashboard Cite

Purpose of the review Sarcopenic obesity is a newly identified pathological entity defined by an increase in body fat mass with an associated sarcopenia, characterized by loss of muscle mass, strength, and function. Recently, the concomitant presence of skeletal alteration with sarcopenic obesity has been described leading to a new clinical entity defined osteosarcopenic obesity (OSO). Many studies have tried to unravel the metabolic complex mechanism leading to this clinical entity in order to understand the pathophysiology of this complex condition with the aim of posing an early diagnosis to improve the therapeutic approaches. The purpose of this narrative review is to highlight and revise recent studies on this issue. Recent findings Recent research in the field of OSO has highlighted the role of nutrition and physical activity in the development and management of these conditions. While molecular and cellular pathways remain partially understood, there is a growing focus on lifestyle interventions as key factors in reducing the impact of OSO. These studies emphasize the need for early diagnosis and appropriate therapeutic strategies to improve quality of life and decrease morbidity and mortality associated with OSO. Summary Although the pathophysiological pathways underlying OSO are not fully understood, the clinical implications underscore the need for expanded research in this field. This research is crucial for enabling early diagnosis and implementing effective therapeutic interventions, with the goal of reducing morbidity and mortality and enhancing quality of life.

show abstract

Section: Biomarkersmentioning

confidence: 99%

Sarcopenic obesity and the impact on bone health

Migliaccio,

Mocini,

Minnetti

et al. 2024

Current Opinion in Clinical Nutrition &Amp; Metabolic Care

View full text Add to dashboard Cite

show abstract

“…Donini et al (pp. 252-255) in this year's section nicely illustrated that the concomitant presence of sarcopenia, obesity, and osteoporosis ('osteosarcopenic obesity') represents a dreadful trio particularly occurring in postmenopausal women as each of these conditions is related to adverse outcomes in terms of morbidity, quality of life, and mortality [14]. Also, in chronic diseases such as chronic obstructive pulmonary disease (COPD), a greater prevalence of muscle wasting, weakness, and exercise limitations have been observed in females than in males [15,16].…”

mentioning

confidence: 99%